Together, these results support the conclusion that hepatic APOC3 silencing may be more beneficial in the setting of diabetes as it promotes hepatic clearance of smaller cholesterol-containing RLP particles in addition to triglyceride-lowering, while the main effect of ANGPTL3 silencing in diabetes is to lower triglycerides. Here, APOC3 is linked to diabetes mellitus.